Literature DB >> 24997277

Quantitative analysis of drug delivery to the brain via nasal route.

Luba Kozlovskaya1, Mohammed Abou-Kaoud1, David Stepensky2.   

Abstract

The blood-brain barrier (BBB) prevents drugs' permeability into the brain and limits the management of brain diseases. Intranasal delivery is a convenient route of drug administration that can bypass the BBB and lead to a direct delivery of the drug to the brain. Indeed, drug accumulation in the brain following intranasal application of a drug solution, or of a drug encapsulated in specialized delivery systems (DDSs), has been reported in numerous scientific publications. We aimed to analyze the available quantitative data on drug delivery to the brain via the nasal route and to reveal the efficiency of brain drug delivery and targeting by different types of nasally-administered DDSs. We searched for scientific publications published in 1970-2014 that reported delivery of drugs or model compounds to the brain via intranasal and parenteral routes, and contained quantitative data that were sufficient for calculation of brain targeting efficiency. We identified 73 publications (that reported data on 82 compounds) that matched the search criteria and analyzed their experimental settings, formulation types, analytical methods, and the claimed efficiencies of drug brain targeting: drug targeting efficiency (%DTE) and nose-to-brain direct transport (%DTP). Outcomes of this analysis indicate that efficiency of brain delivery by the nasal route differs widely between the studies, and does not correlate with the drug's physicochemical properties. Particle- and gel-based DDSs offer limited advantage for brain drug delivery in comparison to the intranasal administration of drug solution. Nevertheless, incorporation of specialized reagents (e.g., absorption enhancers, mucoadhesive compounds, targeting residues) can increase the efficiency of drug delivery to the brain via the nasal route. More elaborate and detailed methodological and analytical characterizations and standardized reporting of the experimental outcomes are required for reliable quantification of drug targeting to the brain by the nasal route. Quantitative analysis of these data will facilitate the development of DDSs with high brain targeting efficiency.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Brain drug delivery and targeting; Liposomes; Nano-drug delivery systems; Nanoparticles; Nasal route

Mesh:

Substances:

Year:  2014        PMID: 24997277     DOI: 10.1016/j.jconrel.2014.06.053

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  74 in total

1.  Application of computational tools for the designing of Oleuropein loaded nanostructured lipid carrier for brain targeting through nasal route.

Authors:  Sucharitha Palagati; Satyanarayana Sv; Bhaskar Reddy Kesavan
Journal:  Daru       Date:  2019-11-25       Impact factor: 3.117

2.  The Impact of Inhaled Ambient Ultrafine Particulate Matter on Developing Brain: Potential Importance of Elemental Contaminants.

Authors:  Deborah A Cory-Slechta; Marissa Sobolewski; Elena Marvin; Katherine Conrad; Alyssa Merrill; Tim Anderson; Brian P Jackson; Gunter Oberdorster
Journal:  Toxicol Pathol       Date:  2019-10-14       Impact factor: 1.902

3.  In Vivo Pharmacokinetics of Puerarin via Different Drug Administration Routes Based on Middle Cerebral Artery Occlusion Model.

Authors:  Pengyue Li; Jie Bai; Boyu Dong; Yang Lu; Shengwei Zhang; Shuang Guo; Ning Tan; Mengdi Zhao; Shouying Du; Puning Cao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

4.  Intranasal delivery of α-asarone to the brain with lactoferrin-modified mPEG-PLA nanoparticles prepared by premix membrane emulsification.

Authors:  Linmei Pan; Jing Zhou; Feng Ju; Huaxu Zhu
Journal:  Drug Deliv Transl Res       Date:  2018-02       Impact factor: 4.617

5.  Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling.

Authors:  Qianwen Wang; Yufeng Zhang; Chun-Ho Wong; H Y Edwin Chan; Zhong Zuo
Journal:  AAPS J       Date:  2017-12-27       Impact factor: 4.009

6.  NRG1-ErbB4 signaling promotes functional recovery in a murine model of traumatic brain injury via regulation of GABA release.

Authors:  Weike Deng; Fei Luo; Bao-Ming Li; Lin Mei
Journal:  Exp Brain Res       Date:  2019-11-13       Impact factor: 1.972

7.  "Tau immunotherapy: Hopes and hindrances".

Authors:  Koorosh Shahpasand; Alireza Sepehri Shamloo; Seyed Massood Nabavi; Kun Ping Lu; Xiao Zhen Zhou
Journal:  Hum Vaccin Immunother       Date:  2017-12-01       Impact factor: 3.452

8.  Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells.

Authors:  Gisele C Vaz; Neeru M Sharma; Hong Zheng; Matthew C Zimmerman; Robson S Santos; Frederic Frezard; Marco A P Fontes; Kaushik P Patel
Journal:  J Neurosci Methods       Date:  2016-08-11       Impact factor: 2.390

Review 9.  Nanomaterial-based blood-brain-barrier (BBB) crossing strategies.

Authors:  Jinbing Xie; Zheyu Shen; Yasutaka Anraku; Kazunori Kataoka; Xiaoyuan Chen
Journal:  Biomaterials       Date:  2019-09-14       Impact factor: 12.479

10.  Oxytocin by intranasal and intravenous routes reaches the cerebrospinal fluid in rhesus macaques: determination using a novel oxytocin assay.

Authors:  M R Lee; K B Scheidweiler; X X Diao; F Akhlaghi; A Cummins; M A Huestis; L Leggio; B B Averbeck
Journal:  Mol Psychiatry       Date:  2017-03-14       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.